08/19/2023
Reposted from CPhA:
Good afternoon,
While you may have received some of this information already, we wanted to share some details about an anticipated shortage of Ozempic. CPhA has been in discussion with the manufacturer Novo Nordisk and Health Canada to understand the situation and discuss the implications on pharmacy teams.
Shortage Overview
Novo Nordisk Canada is anticipating a shortage of the Ozempic 1mg pen due to increased global demand for the medication.
Anticipated shortage date: late August through early October. A more stable supply is expected in October 2023.
Ozempic is available in 2 other formats. There are currently no supply disruptions with the Ozempic 0.25 mg and 0.5 mg pens
Health Canada has also published a drug supply notice webpage about the shortage with information for consumers.
Information for pharmacy from Novo Nordisk
The manufacturer has already circulated a communication to pharmacies across Canada that provides an overview for pharmacists:
During the period of late August to early October, delivery to pharmacies in Canada may be delayed and as a result, patients may experience short term, intermittent delays receiving the 1 mg pens.
Novo Nordisk is encouraging pharmacists to limit refill prescriptions to a 30-day supply, where possible.
Patients are advised to contact their pharmacy ahead of running out of their current supply.
While the 0.25 mg or 0.5 mg formats of Ozempic are currently available for patients with type 2 diabetes across Canada and may be an option for some patients to mitigate the impacts of a supply disruption of the 1 mg format, it will be important to avoid further shortages.
Patients who cannot fill their 1mg Ozempic prescriptions are encouraged to consult with their health-care provider/prescriber to discuss appropriate interim solutions/alternatives.
Media
Given the significant international media profile of Ozempic over the past year or so, it’s expected that this shortage will receive considerable media attention. CPhA has already started receiving media requests. We will continue to provide a pharmacist perspective and highlight the ongoing pressures that drug shortages are placing on pharmacy teams.
Next steps
CPhA is exploring additional ways to support pharmacists during this shortage including developing a clinical resource on alternatives. We will continue to engage with the manufacturer, Health Canada and others and provide any updates.